Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized trial of androgen deprivation therapy with or without docetaxel in metastatic prostate cancer
2004-001984-22Phase 3Completed
- Sponsor
- Unicancer
- Start
- Dec 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel, goserelin and nilutamide in Metastatic Prostate Cancer (mPC) and prostate adenocarcinoma (2 arms), sponsored by Unicancer. Primary endpoint: Overall survival at 36 months. Started Dec 2006; status: completed.
02
Drugs
docetaxelgoserelinnilutamide
03
Conditions
Metastatic Prostate Cancer (mPC)prostate adenocarcinoma
Beyond the preview
Go deeper on 2004-001984-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001984-22.